Drugs modulating the L-arginine:NO:cGMP pathway – current use in therapy

Open access


Nitric oxide (NO) is a relatively novel messenger that plays a significant role in a wide range of physiological processes. Currently, it is known that, both, lack and excess of NO can cause diseases, thus a lot of substances have been discovered and utilized which can change the concentration of this molecule within the organism. The aim of the present work is to provide an overview of currently used agents modulating the L-arginine:NO:cGMP pathway, as well as to summarize current understanding of their pharmacological profiles. Nowadays, most of these agents are employed particularly in the treatment of cardiovascular diseases. Further studies can hold promise for enhancing the therapeutic equipment for a variety of other impairments, such as osteoporosis, and also in treatments of the central nervous system.

1. Akmal A.H., Hasan M.: Role of nitric oxide in management of acute respiratory distress syndrome. Ann. Thorac. Med., 3, 100-103, 2008.

2. Amoruso A. et al.: Characterization of the anti-inflammatory properties of NCX 429, a dual-acting compound releasing nitric oxide and naproxen. Life Sci. 126, 28-36, 2015.

3. Atkinson T.J. et al. What’s new in NSAID pharmacotherapy: oral agents to injectables. Pain Med. 1,S11-7, 2013.

4. Barnett C.F., Machado R.F.: Sildenafil in the treatment of pulmonary hypertension. Vasc. Health Risk. Manag., 2, 411-422, 2006.

5. Boden W.E. et al.: Role of short-acting nitroglycerin in the management of ischemic heart disease. Drug. Des. Devel. Ther., 9, 4793-4805, 2015.

6. Bruckdorfer R.: The basics about nitric oxide. Mol. Aspects Med., 26, 3-31, 2005.

7. Buchwalow I. et al.: L-arginine-NO-cGMP signalling pathway in pancreatitis. Sci. Rep., 3, 1899, 2013.

8. Butler A.R., Feelish M.: Therapeutic uses of inorganic nitrite and nitrate: from the past to the future. Circulation, 117, 2151-2159, 2008.

9. Cannon R.O.: Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin. Chem., 44, 1809-1819, 1998.

10. Chen Y. et al.: Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator. Arterioscl. Throm. Vas., 23, 26-36, 2003.

11. DiBlasi R.M., Myers T.R., Hess D.R.: Evidence-based clinical practice guideline: inhaled nitric oxide for neonates with acute hypoxic respiratory failure. Respir. Care., 55, 1717-1745, 2010.

12. DiNicolantonio J.J. et al.: β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart, 2, 2015.

13. Evans J.D., Hill S.R: A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil. Patient. Prefer. Adherence, 9, 1159-1164, 2015.

14. Fongemie J., Felix-Getzik E.: A Review of Nebivolol Pharmacology and Clinical Evidence. Drugs, 75, 1349-1371, 2015.

15. Forstermann U., Sessa W.C.: Nitric oxide synthases: regulation and function. Eur. Heart J., 33, 829-837, 2012.

16. Garry P. S. et al.: The role of the nitric oxide pathway in brain injury and its treatment - From bench to bedside. Exp. Neurol., 263, 235-243, 2015.

17. Guix F. X. et al.: The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol., 76, 126-152, 2005.

18. Hakky T.S., Jain L.: Current use of phosphodiesterase inhibitors in urology, Turk. J. Urol., 41, 88-92, 2015.

19. Hambrecht R. et al.: Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation. J. Am. Coll. Cardiol., 35, 706-713, 2000.

20. Herchuelz A. et al.: Clinical pharmacokinetics of once - daily molsidomine: From immediate - release to prolonged - release once - daily formulations. Am. J. Drug Delivery., 2, 131-141, 2004.

21. Hiremath J.G. et al.: Pharmaceutical aspects of nicorandil. Int. J. Pharm. Pharm. Sci., 2, 24-29, 2010.

22. Horinaka S. et al.: Nicorandil protects against lethal ischemic ventricular arrhythmias and up-regulates endothelial nitric oxide synthase expression and sulfonylurea receptor 2 mRNA in conscious rats with acute myocardial infarction. Cardiovasc. Drugs Ther., 18, 13-22, 2004.

23. Hottinger D.G. et al.: Sodium nitroprusside in 2014: A clinical concepts review. J. Anaesthesiol. Clin. Pharmacol., 30, 462-471, 2014.

24. Ignarro L.J., Napoli C., Loscalzo J.: Nitric Oxide Donors and Cardiovascular Agents Modulating the Bioactivity of Nitric Oxide. Circ. Res., 90, 21-28, 2002.

25. INOMAXR website [online]. [access: November 13, 2015]. Available at: < http://inomax.com/>.

26. Kannam J., Gersh B.J.: Nitrates in the management of stable angina pectoris [online]. [access: November 13, 2015]. Available at: .

27. Kinoshita M., Sakai K.: Pharmacology and therapeutic effects of nicorandil. Cardiovasc. Drugs Ther., 4, 1075-1088, 1990.

28. Kirkeboen K.A., Strand O.A.: Nitric oxide - an important mediator in sepsis? Tidsskr. Nor. Laegeforen., 119, 4061-4065, 1999.

29. Kopkan L., Cervenka L.: Renal interactions of renin-angiotensin system, nitric oxide and superoxide anion: implications in the pathophysiology of salt-sensitivity and hypertension. Physiol. Res., 58, S55-S67, 2009.

30. Kuhl S.J, Rosen H.: Nitric oxide and septic shock. From bench to bedside. West. J. Med., 168, 176-181, 1998.

31. Lakshminrusimha S.: The Pulmonary Circulation in Neonatal Respiratory Failure. Clin. Perinatol,. 39, 655-683, 2012.

32. Lerman A. et al.: Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation, 97, 2123-2128, 1998.

33. Ma F.X., Han Z.C.: Statins, nitric oxide and neovascularization, Cardiovasc. Drug Rev., 23, 281-292, 2005.

34. Maffei A., Lembo G.: Nitric oxide mechanisms of nebivolol. Ther. Adv. Cardiovasc. Dis., 3, 317-327, 2009.

35. Moncada S., Higgs E.A: The discovery of nitric oxide and its role in vascular biology. Br. J. Pharmacol., 147, S193-S201, 2006.

36. Munzel T., Gori T.: Nebivolol: the somewhat-different betaadrenergic receptor blocker. J. Am. Coll. Cardiol., 54, 1491-1499, 2009.

37. Munzel T.: Recent findings on nitrates: their action, bioactivation and development of tolerance. Dtsch. Med. Wochenschr., 133, 2277-2282, 2008.

38. Nichols S.P.et al.: Local delivery of nitric oxide: targeted delivery of therapeutics to bone and connective tissues. Adv. Drug Deliv. Rev. 64, 1177-1188, 2012.

39. Nossaman V.E. et al.: Nitrates and Nitrites in the Treatment of Ischemic Cardiac Disease. Cardiol. Rev., 18, 190-197, 2011.

40. Orzelska J., Talarek S.: The current approach to the central effects of sildenafil - role of nitric oxide: cGMP pathway. Ann. UMCS Lublin, Sectio DDD, 21, 139-147, 2008.

41. Pacurari M. et al.: The renin-angiotensin-aldosterone system in vascular inflammation and remodeling. Int. J. Inflam, Article ID 689360, doi: 10.1155/2014/689360, 2014.

42. Parker J.D., Gori T.: Tolerance to the organic nitrates: new ideas, new mechanisms, continued mystery. Circulation, 104, 2263-2265, 2001.

43. Reden J.: Molsidomine. Blood Vessels, 27, 282-294, 1990.

44. Rossaint R. et al.: Inhaled Nitric Oxide for the Adult Respiratory Distress Syndrome. N. Engl. J. Med., 328, 399-405, 1993.

45. Schirmer S.H. et al.: Nitric oxide-donating statins: a new concept to boost the lipid-independent effects. Cardiovasc. Res., 94, 395-397, 2012.

46. Scholtholt J. (1985). Molsidomine. In: Clinical Pharmacology of Anti-anginal Drugs. Abshagen U. (editors). Springer - Verlag Berlin Heidelberg; p. 365-377.

47. Stolbach A., Chanmugam A.: Antihypertensive agents, 2015 [online]. [access: November 13, 2015]. Available at:

48. The Official Website of Nobel Prize [online]. [access: November 13, 2015]. Available at: http://www.nobelprize.org/nobel_prizes/medicine/laureates/1998/illpres/

49. Wimalawansa J.: Nitric oxide: new evidence for novel therapeutic indications. Expert. Opin. Pharmacother., 9, 1935-1954, 2008.

50. Yaseen H., Darwich M., Hamdy H.: Is Sildenafil an Effective Therapy in the Management of Persistent Pulmonary Hypertension? J. Clin. Neonatol., 1, 171-175, 2012.

51. Zhou L., Zhu D.Y.: Neuronal Nitric oxide synthase: structure, subcellural localization, regulation and clinical implications. Nitric Oxide, 20, 223-230, 2009.

Current Issues in Pharmacy and Medical Sciences

Formerly Annales UMCS Sectio DDD Pharmacia

Journal Information

CiteScore 2017: 0.22

SCImago Journal Rank (SJR) 2017: 0.131
Source Normalized Impact per Paper (SNIP) 2017: 0.200

Cited By


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 163 163 32
PDF Downloads 57 57 11